NCT07763951已完成不适用
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects Under Fast Conditions.
ADIUM1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2025年12月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Bioequivalence based on the pharmacokinetic parameter: Cmax
研究概览
简要总结
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
详细描述
The study design was a randomized, open-label, two-way, crossover, single-dose, prospective, and longitudinal study, with a 7-day wash-out period before next dosing; to compare the pharmacokinetic profile (Cmax, AUC0-t and AUC0-inf) of two 100 mg/1000 mg sitagliptin/metformin tablet in forty-six (46) healthy male Mexican adult volunteers aged 18 to 55 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age between 18 and 55 years.
- •Clinically healthy according to the updated medical history prior to the start of the study.
- •Not blocked in the COFEPRIS research subject database.
- •Body mass index between 18 and 27 kg/m².
- •Normal vital signs: Heart rate between 60 and 99 beats per minute, respiratory rate between 12 and 20 breaths per minute, systolic blood pressure between 90-130 mmHg, diastolic blood pressure between 60-89 mmHg, and temperature between 36.0 and 37.4°C.
- •Electrocardiogram (ECG) without any signs of pathology.
- •Clinical laboratory test results within normal limits or with clinically insignificant variations.
- •Negative biosafety tests for the presence of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and varicella-zoster virus (VDRL).
- •Negative drug screening tests for amphetamines, benzodiazepines, cocaine, methamphetamines, morphine, and tetrahydrocannabinol (THC).
- •Negative qualitative pregnancy test (for women).
- •Negative breath alcohol test.
- •Research subjects with no history of alcohol abuse or dependence, psychoactive substance abuse, or chronic medication use.
- •Subjects with a signed informed consent form and a signed non-pregnancy commitment letter.
- •Women who are not pregnant or breastfeeding.
- •Women using at least one method of family planning deemed safe by the principal investigator.
排除标准
- •Subjects with a history of hypersensitivity to the study drug.
- •Subjects with lactose intolerance.
- •Subjects with a history of cardiovascular, renal, hepatic, metabolic, gastrointestinal, neurological, endocrine, hematopoietic (any type of anemia), mental illness, or other organic abnormalities that could affect the pharmacokinetic study of the study product.
- •Subjects requiring any medication during the course of the study that interferes with the quantification or pharmacokinetics of the study drug.
- •Subjects who have been exposed to agents known to induce or inhibit hepatic enzyme systems or who have taken potentially toxic medications within 30 days prior to the start of the study.
- •Subjects who, prior to receiving the study drug, have taken medications such as those described in section 3.11 "Drug Interactions."
- •Subjects who have been hospitalized for any reason within sixty days prior to the start of the study or who have been seriously ill within thirty days prior to the start of the study.
- •Subjects who have received an investigational drug within ninety days prior to the start of the study.
- •Subjects who have donated or lost 450 mL or more of blood within sixty days prior to the start of the study.
- •Research subjects with a history of alcohol or psychoactive substance abuse or dependence, or chronic medication use.
- •Subjects who have consumed beverages or foods containing xanthines (coffee, tea, cocoa, chocolate, yerba mate, cola, etc.) or have consumed charcoal-grilled foods within 12 hours prior to administration of the medication dose.
- •Subjects who have consumed grapefruit, cranberry, or pomegranate juice within 12 hours prior to the study.
- •Subjects who have smoked at least 12 hours before the start of the study.
- •Subjects who have ingested alcoholic beverages 48 hours prior to administration of the dose.
- •Positive (qualitative) pregnancy test.
研究组 & 干预措施
Janumet XR
Active Comparator
Janumet XR, 100 mg/1000 mg, ER tablet
干预措施: Janumet XR (Drug)
Sitagliptin/metformin ER
Experimental
Sitagliptin/metformin, 100 mg/1000 mg, ER tablet
干预措施: Sitagliptin/Metformin FDC (Drug)
结局指标
主要结局
Bioequivalence based on the pharmacokinetic parameter: Cmax
时间窗: Through 72 Hours Post Dose
Bioequivalence based on the pharmacokinetic parameter: Cmax
Bioequivalence based on the pharmacokinetic parameter: AUC0-t
时间窗: Through 72 hours Post Dose
Bioequivalence based on the pharmacokinetic parameter: AUC0-t
次要结局
- Characterize the pharmacokinetic parameter: AUC0-inf(Through 72 Hours Post Dose)
- Characterize the pharmacokinetic parameter: time to maximum concentration (tmax)(Through 72 Hours Post Dose)
- Characterize the pharmacokinetic parameter: elimination constant (Ke)(Through 72 Hours Post Dose)
- Characterize the pharmacokinetic parameter: half-life (t1/2)(Through 72 Hours Post Dose)
- Establish the frequency, severity, and seriousness of adverse events that occurred during the study.(Until the final visit (7 days after the last dose))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Vortioxetine in 20 mg Coated Tablets in Healthy Subjects Under Fasting ConditionsNCT07624357ADIUM20
已完成
不适用
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 1000 mg Tablets Under Fed Conditions.NCT07633041ADIUM42
已完成
不适用
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 500 mg Tablets Under Fed Conditions.NCT07633054ADIUM42
已完成
不适用
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 5 mg / 850 mg Tablets Under Fed Conditions.NCT07633015ADIUM42
已完成
不适用
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 850 mg Tablets Under Fed Conditions.NCT07633028ADIUM42